Mounjaro Weekly Injection
  1. Home
  2. Mounjaro
  3. Mounjaro Weekly Injection

Mounjaro Weekly Injection

Mounjaro Weekly Injection is a prescription dual GIP and GLP-1 receptor agonist containing tirzepatide that is used to improve glycemic control in adults with type 2 diabetes and, for certain formulations, to support chronic weight management. It is administered once weekly by subcutaneous injection using a sterile prefilled injection pen. The long-acting formulation provides convenient and reliable weekly treatment with accurate dose delivery.

BUY NOW

Category

Mounjaro Weekly Injection contains tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that helps regulate blood glucose and body weight by enhancing glucose-dependent insulin secretion, reducing glucagon release, slowing gastric emptying, and promoting satiety. The once-weekly injectable formulation delivers sustained therapeutic activity through a prefilled injection pen available in multiple dosage strengths to support individualized treatment. Manufactured under stringent pharmaceutical quality standards, the sterile injection pen is engineered for precise subcutaneous administration and dependable clinical performance throughout the prescribed treatment period. Mounjaro Weekly Injection should be used only under the supervision of a qualified healthcare professional according to the prescribed treatment plan.

Technical Specification

Specification Details
Product Name Mounjaro Weekly Injection
Active Ingredient Tirzepatide
Dosage Form Sterile Prefilled Injection Pen
Route of Administration Subcutaneous Injection
Dosing Frequency Once Weekly
Storage Refrigerate at 2°C–8°C before first use

Product Also Known As

Mounjaro Weekly Injection, Weekly Tirzepatide Injection, Mounjaro Injection Pen, Tirzepatide Injection, Tirzepatide Prefilled Pen, GIP GLP-1 Receptor Agonist Injection, Diabetes Injection Pen